Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T02808 | ||||
| Target Name | Interferon-beta (IFNB1) | ||||
| Synonyms | Interferon beta; IFNbeta; IFNB; IFN-beta; IFB; Fibroblast interferon | ||||
| Target Type | Successful | ||||
| Gene Name | IFNB1 | ||||
| Biochemical Class | Cytokine: interferon | ||||
| UniProt ID | IFNB_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Multiple sclerosis | ||||
| Example drug | Interferon beta-1a | Approved | [1], [2], [3], [4] | ||
| Tissue | Spinal cord | ||||
| Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: 0.05 Z-score: 0.21 P-value: 3.64E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Type 2 diabetes | ||||
| Example drug | PEGylated IFN beta 1-a | Approved | [3], [4], [5], [6] | ||
| Tissue | Liver tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.07 Z-score: -0.25 P-value: 1.91E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Glioma | ||||
| Example drug | Gene therapy, IFN-b | Phase 1 | [7], [3], [4] | ||
| Tissue | Brainstem tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.07 Z-score: -0.63 P-value: 5.84E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Glioma | ||||
| Example drug | Gene therapy, IFN-b | Phase 1 | [7], [3], [4] | ||
| Tissue | White matter | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.57 Z-score: -0.55 P-value: 3.78E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8339). | ||||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | ||||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 4 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
| REF 5 | ClinicalTrials.gov (NCT02234869) Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy. U.S. National Institutes of Health. | ||||
| REF 6 | Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. | ||||
| REF 7 | A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med. 2008 Apr;10(4):329-39. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.